drugset / Trial / NCT00047502
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study if to investigate the effect of lonafarnib (SCH66336) in combination with Gleevec in the treatment of CML.
Timeline
- Start
- 2002-11-01
- Primary completion
- 2006-04-10
- Completion
- 2006-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | Oral |
| Subject | Imatinib | Small molecule | 600 mg | Oral |
| Subject | Lonafarnib | Small molecule | 100 mg | Oral |